Drug Detail

Information about Sprycel + Yervoy

Generic Name
IND
Ipilimumab + dasatinib
Brand Name (US)
Sprycel + Yervoy
Manufacturer
Bristol-Myers Squibb (both)
Drug Type
Tyrosine Kinase Inhibitor, Monoclonal Antibody
Delivery
Oral
Approval Status
Both are approved. This combination is not approved for GIST. It is being evaluated in a phase 1 trial for GIST.
Indications
CML & Melonoma
Overall Strategy
KIT Protein + GIST cell based
Strategy
Block KIT + Stimulate the immune system
Drug Category
KIT inhibitor + CTLA-4 inhibitor

Dasatinib is a KIT/PDGFRA/SRC/ABL inhibitor that is approved for chronic myeloid leukemia. It is not approved for GIST.
Ipilimumab is a CTLA-4 inhibitor and is approved for advanced melanoma (brand name Vervoy). It is the first drug shown to improve overall survival in melanoma. Ipilimumab is a type of immunotherapy that activates T cells, increasing the antitumor response of the immune system.
Note: Proton pump inhibitors (PPI) interfere with the proper absorption of dasatinib, decreasing dasatinib levels by half.
See individual dasatinib and ipilimumab records in this database.